Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Colorectal Disease
Published in: International Journal of Colorectal Disease 10/2013

01-10-2013 | Original Article

Molecular alterations of EGFR in small intestinal adenocarcinoma

Authors: Yan Wang, Cong-Qing Jiang, Jing Guan, Gui-Fang Yang, Jun-Qiu Yue, Hong-Lei Chen, Jing-Ling Xue, Zhi-Gao Xu, Qun Qian, Li-Fang Fan

Published in: International Journal of Colorectal Disease | Issue 10/2013

Login to get access

Abstract

Background and aims

Molecular testing for epidermal growth factor receptor (EGFR) mutations has recently become a standard practice for the management of patients with non-squamous none small cell lung cancer. Primary small intestine adenocarcinoma (SIA) is an uncommon malignancy, and EGFR mutation in the cancer has not been well characterized due to its rarity.

Methods

A micro-tissue array with 53 SIAs and 24 surgically resected primary non-ampullary SIAs were studied. EGFR mutations were analyzed by DNA sequencing in 24 cases with formalin-fixed paraffin-embedded blocks. All 77 cases were examined by immunohistochemistry (IHC) using antibodies specific for the EGFR E746-A750 deletion in exon 19 (DEL), L858R point mutation in exon 21 (L858R), and total EGFR. EGFR amplifications were detected by fluorescence in situ hybridization.

Results

A positive reaction of DEL-specific, L858R-specific, and total EGFR antibodies was detected in seven (9.1 %), 5(6.5 %) and 35 (45.5 %) of 77 SIAs by IHC, respectively. Positive reaction of the three antibodies was not significantly correlated with patient’s age, gender, differentiation, and stage. EGFR gene amplification was assayed in 77 SIAs in micro-tissue array. Of 24 SIA samples that had DNA sequencing, two (8.3 %) harbored exon 19 deletion and one (4.2 %) harbored L858R point mutation. Only one case with EGFR amplification and two cases with polysomy were shown.

Conclusions

Our findings suggested that mutations and amplification in EGFR genes are minor events, and most of SIAs may be unsuitable to EGFR-TKIs treatment.
Literature
1.
Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 59:225–249
2.
The American College of Surgeons Commission on Cancer and the American Cancer Society, Howe JR, Karnell LH et al (1999) Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985–1995. Cancer 86:2693–2706PubMedCrossRef
3.
Dabaja BS, Suki D, Pro B et al (2004) Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 101:518–526PubMedCrossRef
4.
Czaykowski P, Hui D (2007) Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol 19:143–149CrossRef
5.
Koo DH, Yun SC, Hong YS et al (2011) Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer 11:205eCrossRef
6.
Jigyasu D, Bedikian AY, Stroehlein JR (1984) Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 53:23–25PubMedCrossRef
7.
Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16PubMedCrossRef
8.
Sibilia M, Kroismayr R, Lichtenberger BM et al (2007) The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 75:770–787PubMedCrossRef
9.
Riely GJ, Pao W, Pham D et al (2006) Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12:839–844PubMedCrossRef
10.
Mitsudomi T, Kosaka T, Endoh H et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513–2520PubMedCrossRef
11.
Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor under-lying responsiveness of non-small-cell lung cancer to gefitinib. N Engl Med 350:2129–2139CrossRef
12.
Paez JG, Jänne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef
13.
Pao W, Miller V, Zakowski M et al (2004) EGF recep- tor gene mutations are common in lung cancers from “neversmokers” and are associated “with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311PubMedCrossRef
14.
Nomoto K, Tsuta K, Takano T et al (2006) Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 126:608–615PubMedCrossRef
15.
Pan QL, Pao W, Ladanyi M (2005) Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn 7:396–3403PubMedCrossRef
16.
Ohnishi H, Ohtsuka K, Ooide A et al (2006) A simple and sensitive method for detecting major mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene in non-small-cell lung carcinoma. Diagn Mol Pathol 15:101–108PubMedCrossRef
17.
Endo K, Konishi A, Sasaki H et al (2005) Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 50:375–384PubMedCrossRef
18.
Yu J, Kane S, Wu J, Benedettini E et al (2009) Mutation-specific anti-bodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res 15:3023–3028PubMedCrossRef
19.
Kitamura A, Hosoda W, Sasaki E et al (2010) Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res 16:3349–3355PubMedCrossRef
20.
Brevet M, Arcila M, Ladanyi M (2010) Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn 12:169–176PubMedCrossRef
21.
Kato Y, Peled N, Wynes MW et al (2010) Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations. J Thorac Oncol 5:1551–1558PubMedCrossRef
22.
Simonetti S, Molina MA, Queralt C et al (2010) Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer. J Transl Med 8:135eCrossRef
23.
Kawahara A, Yamamoto C, Nakashima K et al (2010) Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. Clin Cancer Res 16:3163–3170PubMedCrossRef
24.
Kawahara A, Azuma K, Sumi A et al (2011) Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 74:35–40PubMedCrossRef
25.
Sun M, Yang F, Shen L et al (2011) Detection of epidermal growth factor receptor mutations in non small cell lung carcinoma by direct sequencing and correlations with clinicopathological characteristics and sample types. Chin J Pathol 40:655–659
26.
Kozu Y, Tsuta K, Kohno T et al (2011) The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma. Lung Cancer 73:45–50PubMedCrossRef
27.
Ladanyi M, Pao W (2008) Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 21:S16–S22PubMedCrossRef
28.
Marks JL, Broderick S, Zhou Q et al (2008) Prognostic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol 3:111–116PubMedCrossRef
29.
Nagahara H, Mimori K, Ohta M et al (2005) Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res 11:1368–1371PubMedCrossRef
30.
Delaunoit T, Neczyporenko F, Limburg PJ et al (2005) Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol 100:703–710PubMedCrossRef
31.
Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92:1331–1346PubMedCrossRef
32.
33.
Lièvre A, Bachet JB, Le Corre D et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995PubMedCrossRef
34.
Shia J, Klimstra DS, Li AR et al (2005) Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18:1350–1356PubMedCrossRef
35.
Overman MJ, Pozadzides J, Kopetz S et al (2010) Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer 102:144–150PubMedCrossRef
Metadata
Title
Molecular alterations of EGFR in small intestinal adenocarcinoma
Authors
Yan Wang
Cong-Qing Jiang
Jing Guan
Gui-Fang Yang
Jun-Qiu Yue
Hong-Lei Chen
Jing-Ling Xue
Zhi-Gao Xu
Qun Qian
Li-Fang Fan
Publication date
01-10-2013
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 10/2013
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-013-1689-6

Other articles of this Issue 10/2013

International Journal of Colorectal Disease 10/2013 Go to the issue

Original Article

Thirty-seven patients treated with the C-seal: protection of stapled colorectal anastomoses with a biodegradable sheath

Letter to the Editor

Meta-analysis of the association between the XRCC1 gene R399Q polymorphism and colorectal cancer: an update

Letter to the Editor

Letter to the editor: obvious association between XRCC1 Arg399Gln polymorphism and colorectal cancer in East Asians

Original Article

An appraisal of lymph node ratio in colon and rectal cancer: not one size fits all

Orignal Article

Neoadjuvant chemotherapy can improve outcome of colorectal cancer patients with unresectable metastasis

Letter to the Editor

New genetic variants of genes MMR in a Spanish family with Lynch syndrome